Patients with early stage pancreatic ductal adenocarcinoma (PDAC) may not benefit from adjuvant therapy after surgery if the tumor is smaller than 1 cm, according to a retrospective analysis published in Cancer.
Although the study indicates a change in the standard of care may be necessary for patients with particularly small tumors, additional studies are needed to validate the findings. Read more . . .